E-Submission
Yeungnam University College of MedicineIndexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
Search
- Page Path
- HOME > Search
Review article
- Biological treatments for severe asthma
- Hyun Jung Jin
- Yeungnam Univ J Med. 2020;37(4):262-268. Published online September 11, 2020
- DOI: https://doi.org/10.12701/yujm.2020.00647
- 6,690 View
- 176 Download
- 9 Crossref
-
Abstract
PDF - Severe asthma patients comprise about 3% to 13% of all asthma patients, but they have higher hospital utilization rates and higher medical costs than those of nonsevere asthma patients. Treatment methods for severe asthma patients are still lacking; however, the recent development of biologics is expected to have a positive effect. The biological therapies developed so far are mainly aimed at treating asthma patients with type 2 inflammation. These biologics have been found to reduce symptoms of asthma, improve lung function, reduce the use of oral corticosteroids, and improve quality of life of patients. This article reviews the mechanism of action and indications for approved biologics and discusses what should be considered when choosing biologics.
-
Citations
Citations to this article as recorded by
- Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
Hanna K. Mandl, Jessa E. Miller, Daniel M. Beswick
Otolaryngologic Clinics of North America.2024; 57(2): 225. CrossRef - Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities
Sara Naharro-González, Clara Lorente-Sorolla, José Manuel Rodrigo-Muñoz, Marcela Valverde-Monge, Erwin Javier Pinillos-Robles, Diana Betancor, Mar Fernández-Nieto, Diana Sánchez-Mellado, Marta Gil-Martínez, Jessica Mireya Santillán-Coello, José Miguel Vil
Biomolecules.2024; 14(1): 126. CrossRef - Biologic Therapies across Nasal Polyp Subtypes
Kody G. Bolk, Sarah K. Wise
Journal of Personalized Medicine.2024; 14(4): 432. CrossRef - Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young, Nathorn Chaiyakunapruk
Journal of Asthma.2023; 60(9): 1702. CrossRef - Tackling the cytokine storm using advanced drug delivery in allergic airway disease
Vyoma K. Patel, Sukriti Vishwas, Rajan Kumar, Gabriele De Rubis, Shakti D. Shukla, Keshav Raj Paudel, Bikash Manandhar, Thakur Gurjeet Singh, Dinesh Kumar Chellappan, Monica Gulati, Indu Pal Kaur, Venkata Sita Rama Raju Allam, Philip M. Hansbro, Brian G.
Journal of Drug Delivery Science and Technology.2023; 82: 104366. CrossRef - The evolving landscape of immunotherapy for the treatment of allergic conditions
Aarti Pandya, Esosa Adah, Bridgette Jones, Rachel Chevalier
Clinical and Translational Science.2023; 16(8): 1294. CrossRef - Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis
Chin Kook Rhee, Jung-Won Park, Heung-Woo Park, You Sook Cho
Allergy, Asthma & Immunology Research.2022; 14(2): 182. CrossRef - The role of peripheral eosinophilia in diagnosing lung disorders: experience from a single pneumonological center
Justyna Fijołek, Elzbieta Wiatr, Dorota Piotrowska-Kownacka, Kazimierz Roszkowski-Sliz
Multidisciplinary Respiratory Medicine.2021;[Epub] CrossRef - Advances in the science and treatment of respiratory diseases
Jin Hong Chung
Yeungnam University Journal of Medicine.2020; 37(4): 251. CrossRef
- Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
First
Prev
